RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
Won't be rushing to give CKD pts gadolinium (and unnecessary NSF risk) based on this meta analysis - 0 cases with only 3 years follow up... https://t.co/urXuw66OKl
Fibrosis nefrogenica sistémica por Gadolinio. Comentaré mañana con Radiología Torrecardenas . Ya hablamos ayer.
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
Important take-away here. 0 cases of NSF in >4900 of Stage 4 or Stage 5 CKD with modern IV gadolinium. This will help inform the risk discussion for cardiac MRIs in this population. https://t.co/mXYQLgk4yr
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Great #visualabstract by @VickiSandys1 🖇️Articulo @JAMA_current: https://t.co/3rekO2xl9R @SENefrologia @sengndi @SOMANEorg @nefrocat
New2Trip: Risk of Nephrogenic Systemic Fibrosis in Patients w/ Stage 4 or 5 Chronic Kidney Disease Receiving Group II Gadolinium-Based Contrast Agent: Systematic Review & Meta-analysis https://t.co/YgHy20Yf0R
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
Important study
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @asupadh: No risk of NSF with Group II Gadolinium in Advanced CKD- reassuring finding. https://t.co/7gG0wH5K3b
0 out of almost 5,000 patients with CKD4 and 5 had NSF after MRI with IV guadolinium administration. https://t.co/4IdzM7hrk3
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
No risk of NSF with Group II Gadolinium in Advanced CKD- reassuring finding. https://t.co/7gG0wH5K3b
RT @fadelrowaie: Risk of NSF in stage 4 or 5 CKD receiveng group 2 gadolinium contrast is zero https://t.co/sJ9YM7RoSV
Risk of NSF in stage 4 or 5 CKD receiveng group 2 gadolinium contrast is zero https://t.co/sJ9YM7RoSV
RT @DamianFog: Attention radiology departments stopping access to MRIs in CKD patients. Explains why I haven’t seen a case.
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
Something to really think about before denying potentially crucial diagnostic imaging to patients with CKD.
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @DamianFog: Attention radiology departments stopping access to MRIs in CKD patients. Explains why I haven’t seen a case.
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
🤔
Attention radiology departments stopping access to MRIs in CKD patients. Explains why I haven’t seen a case.
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.” https://t.co/MZHLZdHj00
RT @MIRimaging: Recent meta-analysis suggests nephrogenic systemic fibrosis may be of limited concern with group II gadolinium-based contra…
https://t.co/tcUgqSwIgt CKD後期のGd造影使用による腎性全身性線維症発症リスクは低い。 もう少し追跡調査が必要なんでしょうが、今まで常識とされてきたことがどんどん変わってきてて面白いです。 ヨード造影剤も腎機能に与える影響は少ないという報告も多く見られるようになってきましたね。
Recent meta-analysis suggests nephrogenic systemic fibrosis may be of limited concern with group II gadolinium-based contrast agents in patents with severe #CKD. https://t.co/d75YOBrVus https://t.co/ZZoM3EWZfp
RT @PeteMorone: Wow! Anyone need a second round of contrast?! @VUMC_Neurosurg @VUMCradiology https://t.co/qj74aPSNUK https://t.co/QONjtWnRe8
RT @markfahlen: With an incidence of only 0.07%, the harms of not getting contrast enhanced MRI studies probably outweighs the risk of this…
RT @markfahlen: With an incidence of only 0.07%, the harms of not getting contrast enhanced MRI studies probably outweighs the risk of this…
RT @markfahlen: With an incidence of only 0.07%, the harms of not getting contrast enhanced MRI studies probably outweighs the risk of this…
RT @markfahlen: With an incidence of only 0.07%, the harms of not getting contrast enhanced MRI studies probably outweighs the risk of this…
With an incidence of only 0.07%, the harms of not getting contrast enhanced MRI studies probably outweighs the risk of this feared but extremely rare complication. Risk of NSF in Stage 4 or 5 CKD After Group II Gadolinium-Based Contrast Agent Receipt https
@JamesNovakNeph @vandyniyyar The Woolen et al paper included 16 publications, 11 retrospective. https://t.co/73lBSSreTL Caution with retrospective studies: 1. underpowered for detecting a rare man-made disease, 2. difficult to diagnose, 3. publication
@Wagner_Nephro @vandyniyyar @Wagner_Nephro, how do you interpret the results of this study? https://t.co/P93Hi8o77y
@M_Elraggal @hswapnil Nop. I do nothing. Unless is Gado, then I do hemo after the study and an extra session. It will remove gado, but the true impact on NSF is unknown. Anyway check this article: https://t.co/TWuffl2SvJ
RT @HFNephrology: Important new meta-analysis about the risk of nephrogenic systemic fibrosis in #CKD with #gadolinium: https://t.co/4hGZpv…
RT @HFNephrology: Important new meta-analysis about the risk of nephrogenic systemic fibrosis in #CKD with #gadolinium: https://t.co/4hGZpv…
Important new meta-analysis about the risk of nephrogenic systemic fibrosis in #CKD with #gadolinium: https://t.co/4hGZpvn9aL
RT @NephroTube: Important Systematic Review and Meta-analysis for a known dilema. Risk of NSF from group II GBCA administration in CKD4/5 <…
Important Systematic Review and Meta-analysis for a known dilema. Risk of NSF from group II GBCA administration in CKD4/5 <0.07%. https://t.co/1qByQbqT0z. #Nephpearls
@Scooby_Ruth @RyCmNi @Menelwencilla Lo del gadolinio también es una exageración: https://t.co/CM065pJLdL
RT @jonherochung: Routine screening for renal failure when using a group II gadolinium agent is technically optional according to the ACR b…
Risk of NSF in Stage 4 or 5 CKD After Group II Gadolinium-Based Contrast Agent Receipt https://t.co/jJdjBsJOiY. Excellent paper showing the risk of NSF is extremely low.
Risk of NSF in Stage 4 or 5 CKD After Group II Gadolinium-Based Contrast Agent Receipt https://t.co/n5tQnaSSIJ
RT @aishaikh: Link for the articles ⚡️Risk of NSF in CKD 👉🏽https://t.co/zSNcxIzpzj ⚡️Membranous Nephropathy 👉🏽https://t.co/wOqKRy7X7U ⚡️Al…
RT @MdFacep: Must read for all acute care physicians. @ACEPNow @EmergencyDocs @aceprogramsny @OhioACEP @californiaacep @CriticalCareNew @R…
【システマチックレビュー・メタアナリシス】Group IIのガドリニウムベースの造影剤を投与されるステージ4/5のCKD患者における腎性全身性線維症(NSF)のリスク(NSF発生率の95%CIの上限値は0.07%であった。上限値は各造影剤のサンプルサイズの違いによりばらつきがあった) https://t.co/9BjDbmz0MC
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis | Chronic Kidney Disease | JAMA Internal Medicine | JAMA Network https://
@InternaUninorte
RT @aishaikh: Link for the articles ⚡️Risk of NSF in CKD 👉🏽https://t.co/zSNcxIzpzj ⚡️Membranous Nephropathy 👉🏽https://t.co/wOqKRy7X7U ⚡️Al…
RT @aishaikh: Link for the articles ⚡️Risk of NSF in CKD 👉🏽https://t.co/zSNcxIzpzj ⚡️Membranous Nephropathy 👉🏽https://t.co/wOqKRy7X7U ⚡️Al…
RT @aishaikh: Link for the articles ⚡️Risk of NSF in CKD 👉🏽https://t.co/zSNcxIzpzj ⚡️Membranous Nephropathy 👉🏽https://t.co/wOqKRy7X7U ⚡️Al…
RT @aishaikh: Link for the articles ⚡️Risk of NSF in CKD 👉🏽https://t.co/zSNcxIzpzj ⚡️Membranous Nephropathy 👉🏽https://t.co/wOqKRy7X7U ⚡️Al…